Features of use of angiotensin receptor blockers in clinical practice (focus on candesartan)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Modern treatment of cardiovascular diseases includes the administration of angiotensin II receptor blockers. This article provides an overview of published data on the efficacy, safety, and high adherence to the treatment with candesartan in patients with arterial hypertension, diabetes mellitus, chronic heart failure, and chronic kidney disease. The benefits of candesartan in comparison with other members of this group of drugs are emphasized.

Full Text

Restricted Access

About the authors

Anna G. Evdokimova

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: aevdokimova@rambler.ru
MD, professor of the Department of hospital therapy № 2

Yelena V. Kovalenko

A.I. Yevdokimov Moscow state university of medicine and dentistry

PhD, associate professor of the Department of hospital therapy № 2

Vladimir V. Evdokimov

A.I. Yevdokimov Moscow state university of medicine and dentistry

PhD, associate professor of the Department of hospital therapy № 2

Konstantin I. Tebloev

A.I. Yevdokimov Moscow state university of medicine and dentistry

MD, professor, head of the Department of hospital therapy № 2

Inna A. Shvetsova

A.I. Yevdokimov Moscow state university of medicine and dentistry

Department of hospital therapy № 2

References

  1. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б., Белявская Д.В., Выдрина О.И., Пастернак Е.Ю., Белоусов Д.Ю., Фоминых С.Г. и группа исследователей. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015; 1: 19-25
  2. Морозова Т.Е. Сартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартана. Системные гипертензии. 2013; 2: 13-18
  3. Сидоренко Б.А., Посава П.К., Киктев В.Г. и др. Блокаторы АТ1-ангиотензиновых рецепторов как новая группа антигипертензивных препаратов // Клинич. фармакол. 1999; 6: 64-69
  4. Андрущишина Т.Б., Морозова Т.Е. Антагонисты рецепторов ангиотензина II при лечении кардиоваскулярных заболеваний. ConsiliumMedicum. 2009; 11 (5): 96-101
  5. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Доказательная история кандесартана: прошлое, будущее и настоящее. Сердечная недостаточность. 2015; 16 (5): 303-10
  6. Сиренко Ю.Н., Донченко Н.В. Место кандесартана в современной терапии сердечно-сосудистых заболеваний: обзор доказательств. Артериальная гипертензия. 2011; 4 (18): 114-26
  7. Gleiter C.H., Mörike K.E. Clinical pharmacokinetics of candesartan. ClinPharmacokinet 2002; 41 (1): 7-17
  8. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В. Особенности применения кандесартана в клинической практике. ConsiliumMedicum. 2016; 18 (1): 54-59
  9. Julius S., Nesbitt S.D., Egan B.M. et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker // N. Engl. J. Med. 2006;354:1685-1697.
  10. Клинические рекомендации «Диагностика и лечение артериальной гипертензии» Российского медицинского общества по артериальной гипертонии, 2013 // Кардиологический вестник. 2015; 1:Х
  11. Чазова И.Е. По страницам национальных рекомендаций по лечению артериальной гипертензии: какая стратегия лечения артериальной гипертензии важнее // Эффективная фармакотерапия. Кардиология и ангиология. 2015; 1(24): 32-35
  12. McClellan K.J., Goa K.L. Candesartan cilexetil. A review ofits use in essential hypertension // Drugs. 1998; 56(5): 847-869.
  13. Weisser B., Gerwe M., Braun M., Funken C. Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals Arzneimittelforschung 2005; 55 (9): 505-13.
  14. Weir M.R., Weber M.A., Neutel J.M. et al. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: clinical experience trial. ACTION study investigators // Am J Hypertens. 2001; 14(6): 567-572.
  15. Minatoguchi S., Aoyama T., Kawai N. et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press. 2013; 22 (1): 29-37.
  16. Kario K., Hoshide S., Shimizu M. et al. Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. JHypertens 2010; 28 (7): 1574-83.
  17. Ogihara T., Nakao K., Fukui T. et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51 (2): 393-8.
  18. Ogihara T., Ueshima K., Nakao K. et al. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-JEx). Hypertens Res 2011; 34 (12): 1295-301.1
  19. Matsuno Y., Minatoguchi S., Fujiwara H. et al. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.Blood Press 2011; 20 (1): 12-9.
  20. Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hyperens. 2003 May;21 (5):875-86.
  21. Saxby B.K., Harrington F., Wesnes K.A. et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology 2008; 70 (19 Pt 2): 1858-66.
  22. Cuspidi C., Muiesan M.L., Valagussa L. et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study//J Hypertens. 2002; 20:2293-2300.
  23. Bönner G. Multicentre Study Group. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12,5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press 2008; 2: 22-30.
  24. Bönner G., Landers B., Bramlage P. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderatecardiovascular risk (CHILI Triple T). Vasc Health Risk Manag 2011; 7:85-95.
  25. Lee H.Y., Hong B.K., Chung W.J. et al. Phase IV, 8-week, multicenter,randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. ClinTher 2011; 33 (8): 1043-56.
  26. Lindholm L.H., Persson M., Alaupovic P. et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in North of Sweden Efficacy Evalution (ALPINE study)//J. Hypertens. 2003; 421(8): 1563-1574.
  27. Koyanagi R., Hagiwara N., Yamaguchi J. et al. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. J Cardiol 2013; 62 (4): 217-23.
  28. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Рабочая группа членов Правления Научного общества нефрологов России. Руководитель группы А.В. Смирнов. Левша, СПб, 2012; 54
  29. Нефрология. Клинические рекомендации. Под ред. Шилов Е.М., Смирнов А.В., Козловская Н.Л., М.: ГЭОТАР-Медиа; 2016; 816
  30. Sakamoto M., Suzuki H., Hayashi T. et al. Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure. CardiovascDiabetol 2012; 11: 118-23.
  31. Burgess E., Muirhead N., Rene de Cotret P. et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease // J. Am. Soc. Nephrol. 2009; 20: 893-900.
  32. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., Cooper M.E. For the CALM study group. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study // BMJ. 2000; 321: 1440-1444.
  33. Okumi M., Kawada N., Ichimaru N. et al. Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. ClinExpNephrol 2011; 15 (6): 907-15.
  34. Philipp T., Martinez F., Geiger H. et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25 (3):967-76.
  35. Pfeffer M.A., Swedberg K., Grander C.B. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme // Lancet. 2003; 362: 759-66.
  36. Grander C.B., McMurray J.J.V., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative trial // Lancet. 2003; 362: 772-776.
  37. McMurray J.J.V., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial // Lancet. 2003; 362: 767-71.
  38. Yusuf S., Pfeffer M.A., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARMPreserved trial // Lancet. 2003; 362: 777-781.
  39. Lacourcière Y., Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999; 12(12): 1181-1187.
  40. Elmfeldt D., Olofsson B., Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy // Blood Press. 2002; 11: 293-301.
  41. Zhenfeng Zheng, Huilan Shi, Junya Jia et al. A systematic review andmeta-analysis of candesartan and losartan in the management ofessential hypertension. J Renin Angiotensin Aldosterone Syst 2011;12 (3): 365-74.
  42. Russell D., StMlhammar J., Bodegard J. et al. Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan. J ClinHypertens (Greenwich) 2011; 13 (3): 189-97.
  43. Hasegawa H., Takano H., Kameda Y. et al. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. ClinExpHypertens 2012; 34 (2): 86-91.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies